Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma.

ABSTRACT: Pancreatic carcinoma (PC) is the sixth leading cause of cancer death in both sexes in 2022, responsible for almost 5% of all cancer deaths worldwide; it is characterized by a poor prognosis since most patients present with an unresectable and metastatic tumor. To date, the decreasing trend in mortality rates related to the most common cancers has contributed to making pancreatic cancer a serious public health problem. In the last few years, scientific research has led to many advances in diagnostic approaches, perioperative management, radiotherapy techniques, and systemic therapies for advanced disease, but only with modest incremental progress in PC patient outcomes. Most of the causes of this high mortality are, unfortunately, late diagnosis and an important therapeutic resistance; for

SUBMITTER: Di Marco F 

PROVIDER: S-EPMC11830788 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature